Metabolife Liability Reversal Offers Precedent For Ephedra Defendants
This article was originally published in The Tan Sheet
Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife
You may also be interested in...
A string of settled PPA and ephedra cases will allow Chattem to focus more of its bottom line on product development and potential acquisitions
Metabolife sold its ephedrine alkaloid-containing Metabolife 356 in a "defective condition unreasonably dangerous to an ultimate user," a Birmingham, Ala. federal jury concluded in four cases Nov. 19
Perrigo promotes in pricing, planning